Actavis, Inc. Press Releases

ACT 
$296.14
*  
0.09
0.03%
Get ACT Alerts
*Delayed - data as of Mar. 4, 2015  -  Find a broker to begin trading ACT now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    ACT After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Actavis Confirms District Court Ruling In Atelvia® Patent Litigation
3/4/2015 5:45:00 PM - PR Newswire


Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan
3/3/2015 7:30:00 PM - PR Newswire


Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan
3/2/2015 5:00:00 PM - PR Newswire


Fitch Rates Actavis' Bonds 'BBB-'; Outlook Stable
3/2/2015 10:49:00 AM - Business Wire


Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin)
3/2/2015 8:30:00 AM - PR Newswire


Actavis Announces Proposed Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan
3/2/2015 7:57:00 AM - PR Newswire


Actavis and Medicines360 Announce FDA Approval of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
2/27/2015 8:00:00 AM - PR Newswire


Actavis Receives U.S. FDA Approval for AVYCAZ™ (CEFTAZIDIME-AVIBACTAM)
2/25/2015 5:21:00 PM - PR Newswire


Actavis Announces Pricing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan
2/25/2015 8:00:00 AM - PR Newswire


Actavis Confirms Generic Uceris® Patent Challenge
2/24/2015 4:05:00 PM - PR Newswire


Actavis Receives Final Approval for Generic Version of Subutex®
2/20/2015 8:45:00 AM - PR Newswire


Actavis Announces Proposed Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan
2/19/2015 7:38:00 AM - PR Newswire


Actavis Announces Intention to Adopt "Allergan" Corporate Name
2/18/2015 7:00:00 AM - PR Newswire


Actavis Outlines Standalone Pharmaceutical Pipeline at Investor Meeting
2/18/2015 6:45:00 AM - PR Newswire


Actavis Non-GAAP Net Revenue Increases 44% to $4 Billion in Fourth Quarter 2014; Non-GAAP EPS Increases 23% to $3.91; Increases 2015 Standalone Forecast
2/18/2015 6:30:00 AM - PR Newswire


Actavis Confirms Temporary Injunction From Appeals Court Related to Generic Pulmicort RESPULES®
2/17/2015 5:13:00 PM - PR Newswire


Actavis Launches Generic Pulmicort RESPULES®
2/13/2015 4:28:00 PM - PR Newswire


Actavis to Divest Pharmatech to TPG
2/13/2015 8:30:00 AM - PR Newswire


Actavis launches the "Unconditional Love" Campaign to Recognize Alzheimer's Disease Caregivers
2/13/2015 8:00:00 AM - PR Newswire


Actavis to Divest Doryx® to Mayne Pharma
2/9/2015 5:23:00 PM - PR Newswire


CVS Health Announces Data from Smoking Cessation Outreach on One-Year Anniversary of Decision to Stop Tobacco Sales
2/5/2015 12:45:00 PM - PR Newswire


Actavis to Divest Rights to Branded Respiratory Portfolio in the U.S. and Canada to AstraZeneca
2/5/2015 2:05:00 AM - PR Newswire


Actavis Announces FDA Acceptance of sNDA to Expand TEFLARO® (ceftaroline fosamil) Labeling
2/4/2015 8:00:00 AM - PR Newswire


Sally Beauty Holdings, Inc. Announces Conference Call to Review Fiscal 2015 First Quarter Financial Results on February 5, 2015 at 10:00 a.m. (Central)
1/26/2015 5:30:00 PM - Business Wire


Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC
1/26/2015 5:30:00 PM - PR Newswire
▲3.82 % Price Change since this news event. The Volume Ratio is 0.99.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day